Is there a role of sentinel lymph node biopsy in ductal carcinoma in situ?: analysis of 587 cases
- 22 March 2006
- journal article
- Published by Springer Nature in Breast Cancer Research and Treatment
- Vol. 98 (3) , 311-314
- https://doi.org/10.1007/s10549-006-9167-2
Abstract
The role of sentinel lymph node biopsy (SLNB) in patients with a core needle-biopsy diagnosis of ductal carcinoma in situ (DCIS) has been intensely debated. Core needle-biopsy has an inherent sampling error leading to histologic underestimation of invasive disease. If SLNB is not performed at the time of the definitive operative procedure, patients found to have an invasive cancer, will require a second operative procedure. The study was designed to determine when the risk of finding invasive disease on final pathology in patients with an initial diagnosis of DCIS was sufficiently high to justify the use of SLNB. We identified 587 women with an initial core needle-biopsy diagnosis of DCIS in the prospective Breast Test Wales (BTW) database from 1995 through 2005. A variety of clinical, mammographic and histologic features were identified and correlated with the presence of invasion at excision using univariate and multivariate analyses. Median age of patients at the time of diagnosis was 58 years (range 41 to 83 years). 201 patients (36%) were treated by mastectomy and 354 (64%) by breast conservation surgery. 220 of 587 patients (38%) were found to have invasive disease on final pathology. On univariate analysis, the rate of upstaging was related to the presence of a clinically palpable mass and size of the mass (both pppp<0.0001). Age, grade of DCIS, microinvasion and presence of comedonecrosis did not help in distinguishing between patients with DCIS and those upstaged to invasive carcinoma at definitive surgery. Axillary nodal staging (four node sampling or clearance) was done at the time of surgery in 269 patients. Axillary nodal metastases were found in 35 of 269 patients (13%). All 35 patients had invasive carcinoma on final pathology. The indiscriminate use of SLNB in patients with DCIS seems excessive. Our study suggests that patients with a mass on clinical examination or mammogram have an increased risk of invasive disease at the time of definitive operative procedure and should undergo SLNB at the initial procedure. In addition, SLNB should be performed in patients undergoing mastectomy because mastectomy precludes SLNB if invasive disease is subsequently discovered.Keywords
This publication has 11 references indexed in Scilit:
- An update of sentinel lymph node mapping in patients with ductal carcinoma in situThe American Journal of Surgery, 2005
- Predictors of invasive breast cancer in patients with an initial diagnosis of ductal carcinoma in situ: A guide to selective use of sentinel lymph node biopsy in management of ductal carcinoma in situJournal of the American College of Surgeons, 2005
- Core biopsy diagnosis of ductal carcinoma in situ: An indication for sentinel lymph node biopsyCurrent Surgery, 2005
- The Finding of Invasive Cancer After a Preoperative Diagnosis of Ductal Carcinoma-In-Situ: Causes of Ductal Carcinoma-In-Situ Underestimates With Stereotactic 14-Gauge Needle BiopsyAnnals of Surgical Oncology, 2003
- Predicting Invasion in the Excision Specimen From Breast Core Needle Biopsy Specimens With Only Ductal Carcinoma In SituArchives of Pathology & Laboratory Medicine, 2002
- Stereotactic Breast Biopsy of Nonpalpable Lesions: Determinants of Ductal Carcinoma in Situ Underestimation RatesRadiology, 2001
- Ductal Carcinoma in Situ Diagnosed with Stereotactic Core Needle Biopsy: Can Invasion Be Predicted?Radiology, 2000
- Primary tumour characteristics and axillary lymph node status in breast cancerBritish Journal of Cancer, 1999
- Stereotactic biopsy of ductal carcinoma in situ of the breast using an 11-gauge vacuum-assisted device: persistent underestimation of disease.American Journal of Roentgenology, 1999
- Axillary lymph node dissection for t1a breast carcinoma. Is it indicated?Cancer, 1994